Testing chemoradiotherapy for esophageal and stomach junction cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 3 study tests a cancer treatment plan that combines chemotherapy and radiation for people with esophageal or esophagus-stomach junction cancer. It aims to see whether this approach works better than standard care for cancers at stages I to IVA.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You have confirmed esophageal or esophagus-stomach junction cancer (either squamous cell or adenocarcinoma)
- Your cancer is staged I to IVA (AJCC 8th edition)
- Your general health score (ECOG) is 0 or 1, meaning you can do daily activities with little help
- Your blood counts and organ blood tests are within required limits (like hemoglobin, white cells, platelets, and liver/kidney tests)
- Your cancer does not already have spread to distant organs (like liver, lung, bone, or brain)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial compares different “treatments before surgery” for people with esophageal (or esophagus-to-stomach) cancer. It aims to see which approach works better to control the cancer and improve outcomes after surgery.
This study checks whether MRI and CT scans can better measure how esophageal or stomach-junction tumors respond during chemoradiotherapy and help doctors map the exact treatment area. It may help improve targeting while you receive standard treatment.
This trial studies whether adding an immunotherapy drug (sintilimab) to standard chemotherapy (S-1 and oxaliplatin) can better treat locally advanced cancer at the junction of the esophagus and stomach. It may help shrink the tumor and control the cancer before or around surgery.
This Phase 1/2 trial tests a treatment plan using chemotherapy plus radiation for esophageal squamous cell cancer that cannot be removed with surgery. It may help shrink or control the cancer and guide safer dosing, but it’s only for people with specific tumor stage, health status, and blood test results.
This Phase 2 study tests a combination of chemotherapy (5-FU/leucovorin plus irinotecan and oxaliplatin) together with radiation for certain types of esophagus/stomach-junction cancer. It may help shrink tumors and control cancer that is locally advanced but not spread to distant organs.
This trial compares two treatment approaches for a specific type of cancer at the junction of the esophagus and stomach. One approach combines chemotherapy before and after surgery, while the other adds radiation before surgery. The goal is to see which approach helps patients live longer with fewer side effects.
Hear when a new Esophagus Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.